Drug Type Small molecule drug |
Synonyms Florastamin[18F], FC-303 |
Target |
Action inhibitors, enhancers |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Adenocarcinoma of prostate | Phase 3 | China | 20 Oct 2023 | |
| Localized Prostate Carcinoma | Phase 3 | China | 20 Oct 2023 | |
| Oligometastatic Prostate Carcinoma | Phase 3 | China | 20 Oct 2023 | |
| PSMA-Positive Prostatic Cancer | Phase 3 | China | 13 Sep 2023 | |
| Metastatic Prostate Carcinoma | Phase 3 | United States | 08 May 2023 | |
| Prostatic Cancer | Phase 3 | South Korea | 13 Aug 2021 |
Phase 3 | 138 | cyttxgejhb(gbdunacmyi) = gidvscdqqr nuxaffuwkr (haamkhrmxg ) View more | Positive | 10 Jul 2025 | |||
Phase 1 | 12 | (MRI with the best performing threshold of ≥ 4) | aimomrbqkv(nqnukwnwaa) = bcxcgrrvzr fdrdvqzaoj (xyhwsiavcn ) View more | Positive | 07 Dec 2024 | ||
(at 60 minutes) | aimomrbqkv(nqnukwnwaa) = rnvuhvqsro fdrdvqzaoj (xyhwsiavcn ) View more |





